Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezafibrate pretreatment plus peginterferon alfa-2a/ribavirin in untreated chronic hepatitis C genotype 1
2005-003648-70Phase 3Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bezafibrate, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Sustained virological response. Started Feb 2007; status: terminated.
02
Drugs
bezafibratepeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-003648-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003648-70.